FrancophonIA/ELRC3.0 huggingface dataset:
English: Similar to the first study the incidence of VTE during extended prophylaxis was significantly lower for enoxaparin sodium compared to placebo for both total VTE (enoxaparin sodium 21 [16%] versus placebo 45 [34.4%]; p=0.001) and proximal DVT (enoxaparin sodium 8 [6.1%] versus placebo 28 [21.4%]; p=<0.001).
Croatian: Slično kao i u prvom ispitivanju, incidencija VTE-a tijekom produljene profilakse bila je značajno niža uz enoksaparinnatrij nego uz placebo i za ukupni VTE (21 uz enoksaparinnatrij [16%] naspram 45 uz placebo [34,4%]; p = 0,001) i za proksimalni DVT (8 uz enoksaparinnatrij [6,1%] naspram 28 uz placebo [21,4%]; p < 0,001).
English: • Enoxaparin sodium is not recommended for patients with end stage renal disease (creatinine clearance <15 mL/min) due to lack of data in this population outside the prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Croatian: • Enoksaparinnatrij se ne preporučuje za bolesnike u terminalnoj fazi bubrežne bolesti (klirens kreatinina < 15 ml/min) zbog nedovoljno podataka o primjeni u toj populaciji u svim indikacijama osim sprječavanja nastanka krvnih ugrušaka u izvantjelesnoj cirkulaciji tijekom hemodijalize.
English: Enoxaparin sodium 4,000 IU (40 mg) once a day subcutaneously n (%)
Croatian: Enoksaparinnatrij 4000 IU (40 mg) jedanput na dan supkutano n (%)
English: Treatment of deep vein thrombosis with or without pulmonary embolism In a multicentre, parallel group study, 900 patients with acute lower extremity DVT with or without PE were randomized to an inpatient (hospital) treatment of either (i) enoxaparin sodium 150 IU/kg (1.5 mg/kg) once a day subcutaneously, (ii) enoxaparin sodium 100 IU/kg (1 mg/kg) every 12 hours subcutaneously, or (iii) heparin intravenous bolus (5,000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds).
Croatian: U multicentričnom ispitivanju s paralelnim skupinama, 900 bolesnika s akutnim DVT-om donjih ekstremiteta, praćenim PE-om ili bez njega, bilo je randomizirano za bolničko liječenje (i) enoksaparinnatrijem u dozi od 150 IU/kg (1,5 mg/kg) supkutano jedanput na dan, (ii) enoksaparinnatrijem u dozi od 100 IU/kg (1 mg/kg) supkutano svakih 12 sati ili (iii) intravenskim bolusom heparina (5000 IU) nakon kojega je uslijedila kontinuirana infuzija (primijenjena radi postizanja aPTV-a od 55 do 85 sekundi).
English: The mean maximum anti-IIa activity level is observed approximately 3 to 4 hours following subcutaneous injection and reaches 0.13 IU/mL and 0.19 IU/mL following repeated administration of 100 IU/kg (1 mg/kg) twice daily and 150 IU/kg (1.5 mg/kg) once daily, respectively.
Croatian: Srednja vrijednost vršne anti-IIa aktivnosti bilježi se približno 3 do 4 sata nakon supkutane injekcije te doseže vrijednosti od 0,13 IU/ml i 0,19 IU/ml nakon ponovljene primjene doze od 100 IU/kg (1 mg/kg) dvaput na dan odnosno 150 IU/kg (1,5 mg/kg) jedanput na dan.
English: Benzyl alcohol (150 mg in 10.0 mL)
Croatian: Pomoćna(e) tvar(i) s poznatim učinkom Benzilni alkohol (150 mg u 10,0 ml)
English: The following medicinal products may be administered with caution concomitantly with enoxaparin sodium: Other medicinal products affecting haemostasis such as: - Platelet aggregation inhibitors including acetylsalicylic acid used at antiaggregant dose (cardioprotection), clopidogrel, ticlopidine, and glycoprotein IIb/IIIa antagonists indicated in acute coronary syndrome due to the risk of bleeding, - Dextran 40, - Systemic glucocorticoids.
Croatian: Sljedeći se lijekovi mogu primjenjivati zajedno s enoksaparinnatrijem uz oprez: Ostali lijekovi koji utječu na hemostazu, kao što su: - inhibitori agregacije trombocita, uključujući acetilsalicilatnu kiselinu u antiagregacijskoj dozi (kardioprotekcija), klopidogrel, tiklopidin i antagoniste glikoproteina IIb/IIIa indicirane kod akutnog koronarnog sindroma zbog rizika od krvarenja - dekstran 40 - sistemski glukokortikoidi
English: Total VTE
Croatian: Nemojte ga
English: For patients with creatinine clearance [15-30 mL/minute], additional considerations are necessary because elimination of enoxaparin sodium is more prolonged (see section 4.2).
Croatian: Potrebno je dodatno razmotriti primjenu u bolesnika kojima je klirens kreatinina 15-30 ml/min jer je kod njih eliminacija enoksaparina dugotrajnija (vidjeti dio 4.2).
English: Intravenous (Bolus) Injection (for acute STEMI indication only)
Croatian: Intravenska (bolusna) injekcija (samo za akutni STEMI)
English: Obese Patients
Croatian: Pretili bolesnici
English: To obtain a 300 IU/mL (3 mg/mL) solution, using a 6,000 IU (60 mg) enoxaparin sodium pre-filled syringe, it is recommended to use a 50 mL infusion bag (i.e. using either normal sodium chloride 9 mg/mL (0.9%) solution for infusion or 5% glucose in water for injections) as follows:
Croatian: Da bi se dobila otopina od 300 IU/ml (3 mg/ml) kada se koristi napunjena štrcaljka sa 6000 IU (60 mg) enoksaparinnatrija, preporučuje se upotrijebiti infuzijsku vrećicu volumena 50 ml (s običnom otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom vodenom otopinom glukoze za injekcije) na sljedeći način:
English: Dosage table for patients with severe renal impairment (creatinine clearance [15-30] mL/min):
Croatian: Tablica za doziranje u bolesnika s teškim oštećenjem funkcije bubrega (klirens kreatinina: 15-30 ml/min)
English: • Bleeding.
Croatian: • Krvarenje
English: One vial contains enoxaparin sodium 50,000 IU anti-Xa activity (equivalent to 500 mg) in 5.0 mL water for injections.
Croatian: Jedna bočica sadrži 50 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 500 mg) u 5,0 ml vode za injekcije.
English: For all indications except STEMI, no dose reduction is necessary in the elderly patients, unless kidney function is impaired (see below “renal impairment” and section 4.4).
Croatian: Kod svih indikacija osim STEMI-ja nije potrebno prilagođavati dozu u starijih bolesnika, osim ako im je narušena bubrežna funkcija (vidjeti odlomak „
English: Very common: Thrombocytosi β
Croatian: Vrlo često: trombocitoz β
English: Inhixa 4,000 IU (40 mg)/0.4 mL is 0.4 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a yellow polypropylene plunger rod.
Croatian: Inhixa 4000 IU (40 mg)/0,4 mL jest 0,4 ml otopine u: - štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i žutim klipom od polipropilena s pričvršćenom iglom i pokrovom za iglu.
English: Enoxaparin sodium is not recommended for patients with end stage renal disease (creatinine clearance < 15 mL/min) due to lack of data in this population outside the prevention of thrombus formation in extra corporeal circulation during haemodialysis.
Croatian: Enoksaparinnatrij se ne preporučuje za bolesnike u terminalnoj fazi bubrežne bolesti (klirens kreatinina < 15 ml/min) zbog nedovoljno podataka o primjeni u toj populaciji kod svih indikacija osim sprječavanja nastanka krvnih ugrušaka u izvantjelesnoj cirkulaciji tijekom hemodijalize.
English: One vial (5.0 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Croatian: Jedna bočica (5,0 ml) sadrži 50 000 IU (500 mg) enoksaparinnatrija.
English: The mean maximum plasma anti-Xa activity level is observed 3 to 5 hours after subcutaneous injection and achieves approximately 0.2, 0.4, 1.0 and 1.3 anti-Xa IU/mL following single subcutaneous administration of 2,000 IU, 4,000 IU, 100 IU/kg and 150 IU/kg (20 mg, 40 mg, 1 mg/kg and 1.5 mg/kg) doses, respectively.
Croatian: Srednja vrijednost vršne plazmatske anti-Xa aktivnosti primjećuje se 3 do 5 sati nakon supkutane injekcije, a iznosi približno 0,2, 0,4, 1,0 odnosno 1,3 anti-Xa IU/ml nakon jednokratne supkutane primjene doze od 2000 IU (20 mg), 4000 IU (40 mg), 100 IU/kg (1 mg/kg) odnosno 150 IU/kg (1,5 mg/kg).
English: Percutaneous coronary revascularization procedures
Croatian: Postupci perkutane koronarne intervencije
English: Solution for injection in multidose vial 1 vial
Croatian: otopina za injekciju u višedoznoj bočici 1 bočica
English: In the clinical studies for treatment of unstable angina and non-Q-wave myocardial infarction, doses were 100 IU/kg (1 mg/kg) subcutaneously every 12 hours, and in the clinical study for treatment of acute STEMI enoxaparin sodium regimen was a 3,000 IU (30 mg) intravenous bolus followed by 100 IU/kg (1 mg/kg) subcutaneously every 12 hours.
Croatian: U kliničkim ispitivanjima primjene za liječenje nestabilne angine i infarkta miokarda bez Q-zupca, doza je iznosila 100 IU/kg (1 mg/kg) supkutano svakih 12 sati, dok je u kliničkom ispitivanju primjene za liječenje akutnog STEMI-ja režim liječenja enoksaparinnatrijem uključivao primjenu intravenske bolusne doze od 3000 IU (30 mg), nakon koje se primjenjivala supkutana doza od 100 IU/kg (1 mg/kg) svakih 12 sati.
English: Common: Thrombocytosisβ
Croatian: Često: trombocitopenija
English: Enoxaparin sodium 2,000 IU (20 mg) once a day subcutaneously n (%)
Croatian: Enoksaparinnatrij 2000 IU (20 mg) jedanput na dan supkutano n (%)
English: Enoxaparin sodium is a low clearance drug with a mean anti-Xa plasma clearance of 0.74 L/h after a 150 IU /kg (1.5 mg/kg) 6-hour intravenous infusion.
Croatian: Enoksaparinnatrij je lijek s niskom stopom klirensa; srednja vrijednost plazmatskog klirensa anti-Xa aktivnosti nakon 6-satne intravenske infuzije doze od 150 IU/kg (1,5 mg/kg) iznosi 0,74 l/h.
English: One pre-filled syringe (0.8 mL) contains 12,000 IU (120 mg) enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka (0,8 ml) sadrži 12 000 IU (120 mg) enoksaparinnatrija.
English: • you are going to receive spinal or epidural anesthesia or lumbar puncture (see section “Operations and
Croatian: • ako ćete primiti spinalnu ili epiduralnu anesteziju ili ići na lumbalnu punkciju (pogledajte odlomak 'Operacije i anestetici'): mora se poštovati vremenski razmak između primjene lijeka
English: Changing from treatment with direct oral anticoagulant to Inhixa Stop taking direct oral anticoagulant.
Croatian: Prelazak s liječenja direktnim oralnim antikoagulansima na Inhixu Prestanite uzimati direktni oralni antikoagulans.
English: CARTON (Packs of 1, 2, 6, 10, 20, 50 or 90)
Croatian: KUTIJA (Pakiranje od 1, 2, 6, 10, 20, 50 ili 90)
English: Inhixa 15,000 IU (150 mg)/1 mL solution for injection
Croatian: Inhixa 15 000 IU (150 mg)/1 ml otopina za injekciju
English: Anti-Xa exposure represented by AUC, at steady-state, is marginally increased in mild (creatinine clearance 50-80 mL/min) and moderate (creatinine clearance 30-50 mL/min) renal impairment after repeated SC 4,000 IU (40 mg) once daily doses.
Croatian: Izloženost anti-Xa aktivnosti, izražena kao AUC, u stanju dinamičke ravnoteže neznatno je povišena kod blagog (klirens kreatinina: 50-80 ml/min) i umjerenog (klirens kreatinina: 30-50 ml/min) oštećenja bubrežne funkcije nakon ponovljene supkutane primjene doze od 4000 IU (40 mg) jedanput na dan.
English: - Changing from treatment with direct oral anticoagulant to Inhixa Stop taking direct oral anticoagulant.
Croatian: - Prelazak s liječenja direktnim oralnim antikoagulansima na Inhixu Prestanite uzimati direktni oralni antikoagulans.
English: Benzyl alcohol (45 mg in 3.0 mL)
Croatian: Pomoćna(e) tvar(i) s poznatim učinkom Benzilni alkohol (45 mg u 3,0 ml)
English: One vial contains enoxaparin sodium 30,000 IU anti-Xa activity (equivalent to 300 mg) in 3.0 mL water for injections.
Croatian: Jedna bočica sadrži 30 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 300 mg) u 3,0 ml vode za injekcije.
English: One vial (5 mL) contains 50,000 IU (500 mg) enoxaparin sodium.
Croatian: Jedna bočica (5 ml) sadrži 50 000 IU (500 mg) enoksaparinnatrija.
English: Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial
Croatian: Inhixa 30 000 IU (300 mg)/3 ml otopina za injekciju u višedoznoj bočici
English: Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30-50 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment, careful clinical monitoring is advised.
Croatian: Iako se ne preporučuje prilagođavanje doze u bolesnika s umjerenim (klirens kreatinina: 30-50 ml/min) i blagim (klirens kreatinina: 50-80 ml/min) oštećenjem bubrežne funkcije, preporučuje se pažljivo kliničko praćenje.
English: Although no dose adjustment is recommended in patients with moderate (creatinine clearance 3050 mL/min) and mild (creatinine clearance 50-80 mL/min) renal impairment, careful clinical monitoring is advised.
Croatian: Iako se ne preporučuje prilagođavanje doze u bolesnika s umjerenim (klirens kreatinina: 3050 ml/min) i blagim (klirens kreatinina: 50 - 80 ml/min) oštećenjem bubrežne funkcije, preporučuje se pažljivo kliničko praćenje.
English: If a manual compression method is used, sheath should be removed 6 hours after the last intravenous/subcutaneous enoxaparin sodium injection.
Croatian: Ako se provodi ručna kompresija, uvodnicu treba ukloniti 6 sati nakon posljednje intravenske./supkutane injekcije enoksparinnatrija.
English: One vial (3.0 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Croatian: Jedna bočica (3,0 ml) sadrži 30 000 IU (300 mg) enoksaparinnatrija.
English: Each pre-filled syringe contains enoxaparin sodium 15,000 IU anti-Xa activity (equivalent to 150 mg) in 1 mL water for injections.
Croatian: Jedna napunjena štrcaljka sadrži 15 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 150 mg) u 1 ml vode za injekcije.
English: Enoxaparin sodium may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection (see section 4.2).
Croatian: Enoksaparinnatrij može se sigurno primijeniti s otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom otopinom glukoze za injekciju (vidjeti dio 4.2).
English: One vial (3 mL) contains 30,000 IU (300 mg) enoxaparin sodium.
Croatian: Jedna bočica (3 ml) sadrži 30 000 IU (300 mg) enoksaparinnatrija.
English: CARTON OF (Packs of 2, 5, 6, 10, 20, 30, 50 or 90)
Croatian: KUTIJA (Pakiranje od 2, 5, 6, 10, 20, 30, 50 ili 90)
English: Inhixa 8,000 IU (80 mg)/0.8 mL is 0.8 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a red polypropylene plunger rod.
Croatian: Inhixa 8000 IU (80 mg)/0,8 ml jest 0,8 ml otopine u: - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i crvenim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
English: Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection
Croatian: Inhixa 4000 IU (40 mg)/0,4 ml otopina za injekciju
English: Inhixa 15,000 IU (150 mg)/1 mL is 1 mL of solution in: - a clear, colourless type I neutral glass syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and a dark blue polypropylene plunger rod.
Croatian: Inhixa 15 000 IU (150 mg)/1 ml jest 1 ml otopine u: - štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil gume i tamnoplavim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
English: Inhixa 10,000 IU (100 mg) /1 mL injection enoxaparin sodium
Croatian: Inhixa 10 000 IU (100 mg)/1 ml otopina za injekciju enoksaparinnatrij
English: Inhixa 50,000 IU (500 mg)/5 mL solution for injection in multidose vial
Croatian: Inhixa 50 000 IU (500 mg)/5 ml otopina za injekciju u višedoznoj bočici
English: Inhixa 6,000 IU (60 mg)/0.6 mL solution for injection
Croatian: Inhixa 6000 IU (60 mg)/0,6 ml otopina za injekciju
English: Packs of: - 2, 10 and 30 pre-filled syringes, - 10 and 30 pre-filled syringes with a needle guard.
Croatian: Pakiranja od: - 2, 10 i 30 napunjenih štrcaljke - 10 i 30 napunjenih štrcaljki sa štitnikom za iglu
English: One pre-filled syringe (0.4 mL) contains 4,000 IU (40 mg) enoxaparin sodium
Croatian: Jedna napunjena štrcaljka (0,4 ml) sadrži 4000 IU (40 mg) enoksaparinnatrija.
English: Each pre-filled syringe of 0.8 mL contains 12,000 IU (120 mg) of enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka od 0,8 ml sadrži 12 000 IU (120 mg) enoksaparinnatrija.
English: Inhixa 2,000 IU (20 mg)/0.2 mL solution for injection
Croatian: Inhixa 2000 IU (20 mg)/0,2 ml otopina za injekciju
English: Each pre-filled syringe contains enoxaparin sodium 4,000 IU anti-Xa activity (equivalent to 40 mg) in 0.4 mL water for injections.
Croatian: Jedna napunjena štrcaljka sadrži 4000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 40 mg) u 0,4 ml vode za injekcije.
English: Each pre-filled syringe contains enoxaparin sodium 6,000 IU anti-Xa activity (equivalent to 60 mg) in 0.6 mL water for injections.
Croatian: Jedna napunjena štrcaljka sadrži 6000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 60 mg) u 0,6 ml vode za injekcije.
English: One vial (10.0 mL) contains 100,000 IU (1000 mg) enoxaparin sodium.
Croatian: Jedna bočica (10,0 ml) sadrži 100 000 IU (1000 mg) enoksaparinnatrija.
English: Inhixa 8,000 IU (80 mg)/0.8 mL solution for injection
Croatian: Inhixa 8000 IU (80 mg)/0,8 ml otopina za injekciju
English: • Inhixa can be given by injection into your vein (intravenous) after certain types of heart attack or operation.
Croatian: • Nakon određenih vrsta srčanog udara ili operacija, Inhixa se može primijeniti injekcijom u venu
English: Changing of anticoagulant treatment - Changing from Inhixa to blood thinners called vitamin-K antagonists (e.g. warfarin) Your doctor will request you perform blood tests called INR and tell you when to stop Inhixa accordingly.
Croatian: Promjena antikoagulansa - Prelazak s lijeka Inhixa na lijekove za razrjeđivanje krvi koji se zovu antagonisti vitamina K (npr. varfarin)
English: Inhixa 12,000 IU (120 mg)/0.8 mL solution for injection
Croatian: Inhixa 12 000 IU (120 mg)/0,8 ml otopina za injekciju
English: In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see section 4.4 and 'Description of selected adverse reactions' below).
Croatian: U kliničkim su ispitivanjima najčešće prijavljene nuspojave bile krvarenja, trombocitopenija i trombocitoza (vidjeti dio 4.4 i odlomak „Opis odabranih nuspojava” u nastavku).
English: In clinical studies, haemorrhages, thrombocytopenia and thrombocytosis were the most commonly reported reactions (see sections 4.4 and “Description of selected adverse reactions” below).
Croatian: U kliničkim su ispitivanjima najčešće prijavljene nuspojave bile krvarenja, trombocitopenija i trombocitoza (vidjeti dijelove 4.4 i „Opis odabranih nuspojava“ u nastavku).
English: Each pre-filled syringe of 0.4 mL contains 4,000 IU (40 mg) of enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka od 0,4 ml sadrži 4000 IU (40 mg) enoksaparinnatrija.
English: Weight
Croatian: Sljedivost
English: Each pre-filled syringe of 0.6 mL contains 6,000 IU (60 mg) of enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka od 0,6 ml sadrži 6000 IU (60 mg) enoksaparinnatrija.
English: Switch between enoxaparin sodium and direct oral anticoagulants (DOAC) For patients currently receiving enoxaparin sodium, discontinue enoxaparin sodium and start the DOAC 0 to 2 hours before the time that the next scheduled administration of enoxaparin sodium would be due as per DOAC label.
Croatian: U bolesnika koji trenutno primaju enoksaparinnatrij, njegovu primjenu treba prekinuti, a primjenu DOAK-a započeti 0 do 2 sata prije nego što je trebala biti primijenjena sljedeća doza enoksaparinnatrija, u skladu s informacijama iz sažetka opisa svojstava lijeka za DOAK.
English: After dilution with sodium chloride 9 mg/ml (0.9%) solution for infusion or 5% glucose solution for injection
Croatian: Nakon razrjeđivanja otopinom natrijeva klorida od 9 mg/ml (0,9 %) za infuziju ili 5 %-tnom otopinom glukoze za injekciju
English: Each pre-filled syringe of 1 mL contains 15,000 IU (150 mg) of enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka od 1 ml sadrži 15 000 IU (150 mg) enoksaparinnatrija.
English: One pre-filled syringe (1 mL) contains 15,000 IU (150 mg) enoxaparin sodium
Croatian: Jedna napunjena štrcaljka (1 ml) sadrži 15 000 IU (150 mg) enoksaparinnatrija.
English: CARTON OF (Packs of 2, 6, 10, 12, 24, 30, 50 or 90)
Croatian: KUTIJA (Pakiranje od 2, 6, 10, 12, 24, 30, 50 ili 90)
English: CARTON OF (Packs of 2, 6, 10, 12, 24 or 30)
Croatian: KUTIJA (Pakiranje od 2, 6, 10, 12, 24 ili 30)
English: CARTON OF (Packs of 2, 6, 10, 12, 20, 24 or 30)
Croatian: KUTIJA (Pakiranje od 2, 6, 10, 12, 20, 24 ili 30)
English: Inhixa 30,000 IU (300 mg)/3 mL solution for injection in multidose vial enoxaparin sodium
Croatian: Inhixa 30 000 IU (300 mg)/3 ml otopina za injekciju u višedoznoj bočici enoksaparinnatrij
English: One pre-filled syringe (0.2 mL) contains 2,000 IU (20 mg) enoxaparin sodium
Croatian: Jedna napunjena štrcaljka (0,2 ml) sadrži 2000 IU (20 mg) enoksaparinnatrija.
English: One vial contains enoxaparin sodium 100,000 IU anti-Xa activity (equivalent to 1000 mg) in 10.0 mL water for injections.
Croatian: Jedna bočica sadrži 100 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 1000 mg) u 10,0 ml vode za injekcije.
English: Each pre-filled syringe of 0.8 mL contains 8,000 IU (80 mg) of enoxaparin sodium.
Croatian: Jedna napunjena štrcaljka od 0,8 ml sadrži 8000 IU (80 mg) enoksaparinnatrija.
English: One pre-filled syringe (0.6 mL) contains 6,000 IU (60 mg) enoxaparin sodium
Croatian: Jedna napunjena štrcaljka (0,6 ml) sadrži 6000 IU (60 mg) enoksaparinnatrija.
English: Switch between enoxaparin sodium and oral anticoagulants Switch between enoxaparin sodium and vitamin K antagonists (VKA) Clinical monitoring and laboratory tests [prothrombin time expressed as the International Normalized Ratio (INR)] must be intensified to monitor the effect of VKA.
Croatian: Prelazak s enoksaparinnatrija na oralne antikoagulanse i obratno Prelazak s enoksaparinnatrija na antagoniste vitamina K i obratno Kliničko praćenje i laboratorijske pretrage (protrombinsko vrijeme izraženo kao internacionalni normalizirani omjer [engl. international normalized ratio, INR] moraju se intenzivirati radi praćenja učinka antagonista vitamina K.
English: Inhixa 15,000 IU (150 mg)/1 mL injection enoxaparin sodium
Croatian: Inhixa 15 000 IU (150 mg)/1 ml otopina za injekciju enoksaparinnatrij
English: Inhixa 6,000 IU (60 mg)/0.6 mL is 0.6 mL of solution in: - a clear, colourless type I neutral glass graduated syringe barrel with fixed needle and needle shield closed by chlorobutyl rubber stopper and an orange polypropylene plunger rod.
Croatian: Inhixa 6000 IU (60 mg)/0,6 ml jest 0,6 ml otopine u: - graduiranoj štrcaljki s tijelom od prozirnog, bezbojnog neutralnog stakla tipa I, zatvorenoj čepom od klorbutil-gume i narančastim klipom od polipropilena, s pričvršćenom iglom i pokrovom za iglu.
English: Each pre-filled syringe contains enoxaparin sodium 12,000 IU anti-Xa activity (equivalent to 120 mg) in 0.8 mL water for injections.
Croatian: Jedna napunjena štrcaljka sadrži 12 000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 120 mg) u 0,8 ml vode za injekcije.
English: Inhixa 100,000 IU (1000 mg)/10 mL solution for injection in multidose vial
Croatian: Inhixa 100 000 IU (1000 mg)/10 ml otopina za injekciju u višedoznoj bočici
English: Each pre-filled syringe contains enoxaparin sodium 8,000 IU anti-Xa activity (equivalent to 80 mg) in 0.8 mL water for injections.
Croatian: Jedna napunjena štrcaljka sadrži 8000 IU anti-Xa aktivnosti enoksaparinnatrija (što odgovara 80 mg) u 0,8 ml vode za injekcije.
English: Solution for injection 2 pre-filled syringes 10 pre-filled syringes 30 pre-filled syringes 10 pre-filled syringes with needle guard 30 pre-filled syringes with needle guard
Croatian: 10 napunjenih štrcaljki 30 napunjenih štrcaljki 10 napunjenih štrcaljki sa štitnikom za iglu 30 napunjenih štrcaljki sa štitnikom za iglu
English: Skin necrosis / cutaneous vasculitis
Croatian: Nekroza kože / kožni vaskulitis